NCT01486277View on ClinicalTrials.gov

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

July 31, 2016

Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
DRUG

Quisinostat, 12 mg

Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).

Trial Locations (13)

Unknown

Pittsburgh

Nantes

Paris

Pessac

Kiel

Minden

Lisbon

Porto

Madrid

Málaga

Valencia

London

Manchester

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01486277 - A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma | Biotech Hunter | Biotech Hunter